贝那利珠单抗可使抗IL-5抗体治疗无法控制的重度哮喘患者痰液嗜酸性粒细胞水平恢复正常：一项单盲、安慰剂对照临床试验。 - Suppr | 超能文献

相似文献

1

Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti-IL-5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial.贝那利珠单抗可使抗IL-5抗体治疗无法控制的重度哮喘患者痰液嗜酸性粒细胞水平恢复正常：一项单盲、安慰剂对照临床试验。

Am J Respir Crit Care Med. 2023 Dec 15;208(12):1330-1335. doi: 10.1164/rccm.202308-1413LE.

2

Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?重度嗜酸性粒细胞性哮喘的治疗——抗白细胞介素-5抗体的一致疗效？

Lancet. 2016 Oct 29;388(10056):2059-2060. doi: 10.1016/S0140-6736(16)31537-9. Epub 2016 Sep 5.

3

Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.贝那鲁肽治疗变应性哮喘：一项随机、双盲、安慰剂对照试验。

Eur Respir J. 2024 Sep 12;64(3). doi: 10.1183/13993003.00512-2024. Print 2024 Sep.

4

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.贝那利珠单抗，一种抗白细胞介素-5 受体 α 的单克隆抗体，作为附加治疗用于严重、未控制、嗜酸性粒细胞性哮喘（CALIMA）患者：一项随机、双盲、安慰剂对照的 3 期试验。

Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5.

5

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.贝那鲁肽对痰嗜酸性粒细胞增多的哮喘患者气道嗜酸性粒细胞的影响。

J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16.

6

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.抗白细胞介素-5治疗在难治性嗜酸性粒细胞性哮喘管理中的疗效和安全性证据。

Ther Adv Respir Dis. 2015 Aug;9(4):135-45. doi: 10.1177/1753465815581279. Epub 2015 Apr 21.

7

Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.本那鲁单抗治疗固定气流受限和严重、未控制的嗜酸性粒细胞性哮喘患者的疗效。

Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15.

8

Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.抗 IL-5/抗 IL-5R 的超级应答者以基线时高痰嗜酸性粒细胞计数为特征。

Thorax. 2023 Nov;78(11):1138-1141. doi: 10.1136/thorax-2022-219781. Epub 2023 Sep 1.

9

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.针对伴有血清免疫球蛋白 E 升高的重症、未控制哮喘患者，按变应原状态评估 benralizumab 的疗效。

Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1.

10

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.非索罗肽，一种前列腺素 D2 受体 2 拮抗剂，在持续性嗜酸性粒细胞性哮喘患者中的应用：一项单中心、随机、双盲、平行分组、安慰剂对照试验。

Lancet Respir Med. 2016 Sep;4(9):699-707. doi: 10.1016/S2213-2600(16)30179-5. Epub 2016 Aug 5.

引用本文的文献

1

Biologics alter the relationship between exhaled nitric oxide fraction and sputum eosinophils in severe T2-high asthma patients.生物制剂改变了重度T2高哮喘患者呼出气一氧化氮分数与痰液嗜酸性粒细胞之间的关系。

ERJ Open Res. 2025 Jun 16;11(3). doi: 10.1183/23120541.00783-2024. eCollection 2025 May.

2

Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP.贝那利珠单抗在降低重度嗜酸性粒细胞性哮喘患者呼出气一氧化氮水平中的疗效：慢性鼻-鼻窦炎伴鼻息肉的作用

J Asthma Allergy. 2025 May 26;18:817-826. doi: 10.2147/JAA.S506835. eCollection 2025.

3

Head-To-Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?